Relating C-reactive Protein to Psychopathology after Cardiac Surgery and Intensive Care Unit

Admission: A Mendelian Randomization Study

Lotte Kok, DVM, MD^{a,b}, Bochao Danae Lin, PhD^c, Juliette Broersen, MSc^b, Erwin Bekema^c, Jelena Medic^c, Kristel R van Eijk, PhD^c, Manon H Hillegers, MD, PhD^{d,e}, Dieuwke S Veldhuijzen, PhD^{a,f}, Jurjen J Luykx, MD, PhD^{c,d,g}

^a Department of Anesthesiology and Intensive Care, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands, ^b Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands, ^c Department of Translational Neuroscience, Human Neurogenetics Unit, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands, ^d Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands, ^e Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Center-Sophia, Rotterdam, The Netherlands, ^f Leiden Institute for Brain and Cognition, Institute of Psychology, Health, Medical and Neuropsychology Unit, Leiden University, Leiden, the Netherlands, ^g Department of Psychiatry, ZNA Hospitals, Antwerp, Belgium.

Running title

C-reactive protein and psychopathology

Keywords

Post-Traumatic Stress Disorder; Depression; Intensive Care; C-reactive Protein

Corresponding author

Lotte Kok, Department of Intensive Care Medicine, University Medical Center Utrecht,

Utrecht, the Netherlands, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands, Phone: +31

88 75 57838, Fax: +31 88 7561160, Email: L.Kok@umcutrecht.nl

Abstract

Patients admitted to an intensive care unit (ICU) are subjected to a high burden of stress, rendering them prone to develop stress-related psychopathology. Dysregulation of inflammation and, more specifically, upregulation of inflammatory markers such as C-reactive protein (CRP) is potentially key in development of post-ICU psychopathology.

To investigate the effects of state-independent CRP on symptoms of post-traumatic stress disorder (PTSD) and depression after ICU admission, we analysed the three leading single nucleotide polymorphisms (SNPs) of loci most strongly associated with blood CRP levels (i.e. rs2794520, rs4420638, and rs1183910) in an ICU survivor cohort. Genetic association was estimated by linear and logistical regression models of individual SNPs and genetic risk score (GRS) profiling. Mendelian Randomization (MR) was used to investigate potential causal relationships.

Single-SNP analyses were non-significant for both quantitative and binary trait analyses after correction for multiple testing. In addition, GRS results were non-significant and explained little variance in psychopathology. Moreover, MR analysis did not reveal any causality and MR-Egger regression showed no evidence of pleiotropic effects ($p\text{-pleiotropy} > 0.05$). Furthermore, estimation of causality between these loci and other psychiatric disorders was similarly non-significant.

In conclusion, by applying a range of statistical models we demonstrate that the strongest plasma CRP-influencing genetic loci are not associated with post-ICU PTSD and depressive symptoms. Our findings add to an expanding body of literature on the absence of associations between trait CRP and neuropsychiatric phenotypes.

Introduction

In the Netherlands, over 80,000 patients are admitted to the Intensive Care Unit (ICU) each year, and this number is increasing (<https://www.stichting-nice.nl/>). After discharge, health-related quality of life is largely determined by mental wellbeing (Iwashyna, 2010; Oeyen *et al*, 2010). The increasing number of ICU survivors combined with a decrease in quality of life renders in-depth studies into determinants of mental health in this patient category timely.

Post-traumatic stress disorder (PTSD) and depression are prevalent mental disorders following ICU admission (Asimakopoulou & Madianos, 2014). Several studies have demonstrated associations between acute high stress exposure due to ICU admission on the one hand, and PTSD and depression on the other (Davydow *et al*, 2013; Schelling *et al*, 2003). Despite the burgeoning body of research highlighting increased incidences of PTSD and depressive symptoms in ICU survivors (Davydow *et al*, 2008; Davydow *et al*, 2009), specific risk factors for developing post-ICU psychopathology remain largely undetermined. A better understanding of the potential mechanisms underlying the development of psychopathology after ICU admission could help to identify patients at risk of psychopathology following ICU stay.

Since dysregulated inflammatory cascades are present in a high number of ICU patients, these might influence the development of psychopathology after discharge (Dieleman *et al*, 2012; Iwashyna, 2010). Evidence suggests that inflammation contributes to the development of PTSD and depression (Miller *et al*, 2009; Raison & Miller, 2011), and – in particular – increased C-reactive protein (CRP) levels are reported to be associated with posttraumatic stress disorder (PTSD), depression, and psychological distress (Danner *et al*, 2003; Eraly *et al*, 2014; Wium-Andersen *et al*, 2013).

Plasma CRP levels are highly affected by myriad state-dependent factors such as diet (King *et al*, 2003), physical activity (Kasapis & Thompson, 2004) and transient systemic infections. To circumvent the influence of these confounding factors on the traits of interest,

we applied Mendelian Randomization (MR), a design that enables assessment of causality between a risk factor and an outcome. MR is based on the assumption that state-dependent features and environmental factors are generally equally distributed over carriers and non-carriers of genetic variants (de Haan *et al*, 2014; van der Weele *et al*, 2014). Thus, by taking genetic variants as proxies for circulating CRP (trait CRP), reverse causation and confounding are less likely to occur than when plasma CRP levels are considered (de Haan *et al*, 2014).

A genome wide association study (GWAS) including over 80,000 individuals found three single nucleotide polymorphisms (SNPs) – rs2794520, rs4420638 and rs1183910 – to be strongly associated with circulating CRP levels (Dehghan *et al*, 2011). The corresponding loci encompass the genes *CRP*, apolipoprotein C1 (*APOC1*) and hepatic nuclear factor 1- α (*HNF1A*), respectively (Dehghan *et al*, 2011). Although other CRP-related SNPs have been investigated in the context of PTSD or depressive symptoms (Ancelin *et al*, 2015; Halder *et al*, 2010; Michopoulos *et al*, 2015; Prins *et al*, 2016), the role that the abovementioned genetic variants play in ICU-related psychopathology have not been studied so far.

Here, we applied MR (including genetic risk scoring) to study the impact of trait CRP on psychopathology following ICU stay. We also investigated genetic pleiotropy between trait CRP and psychopathology following ICU stay. Our design has enabled us to assess causality, which to our knowledge had not been investigated to date.

Methods

Study design, participants and outcome measures

Data were drawn from the Dexamethasone for Cardiac Surgery study (DECS), a longitudinal follow up of patients from a multicenter, double-blind randomized controlled trial (Dieleman *et al*, 2012; Clinicaltrials.gov identifier NCT00293592, N=4494 participants). The aim of this trial was to compare high-dose intravenous dexamethasone (1 mg/kg bodyweight, not exceeding 100 mg) with placebo administration in patients undergoing cardiac surgery who were subsequently submitted to the ICU. Eight cardiac surgery centers in The Netherlands participated, and the study was approved by all applicable research ethics committees (Dieleman *et al*, 2012). The medical Ethics Committee of the University Medical Center Utrecht approved the current follow-up protocol. All subjects participating in the current study signed both the initial and additional informed consent forms.

Participants were recruited between April 13, 2006 and November 23, 2011. DECS included 4494 randomized adult patients requiring a cardiopulmonary bypass during cardiac surgery. Of the original DECS study population, 2458 patients (recruited from five participating centers) were eligible for the follow-up study as the remainder had passed away or exceeded the inclusion criterion of maximum follow up time (i.e., 48 months after randomization).

PTSD symptoms were measured using the Self-Rating Inventory for PTSD (SRIP), a validated Dutch questionnaire (Hovens *et al*, 2002). This 22 item questionnaire addresses DSM-IV-TR criteria of PTSD in the past four weeks. The validated Beck Depression Inventory (BDI-II) (Beck *et al*, 1998) was used to measure depressive symptoms. Items on both questionnaires are scored on a 0-3 Likert scale, with higher scores indicating more severe symptoms. For binary trait analyses, we rated symptoms of PTSD as present in the event of SRIP scores above the validated threshold of 39, which was the case in 10.8% of all

participants, comparable to what has been described in previous studies (van Zelst *et al*, 2003). Symptoms of depression were present in 13.2% of all participants, after applying threshold of 13.5 to the BDI-II score (Dozois *et al*, 1998). A detailed description of the patient selection and measurements is reported elsewhere (Kok *et al*, 2016). For the analyses in this study, we log transformed SRIP and BDI-II variables due to non-normal distributions.

Genotyping procedures

Genomic DNA was extracted from saliva using salivettes (Kleargene™ XL nucleic extraction kits) according to the manufacturer's protocol. Quantity of DNA was measured using Quant-iT™ PicoGreen® dsDNA reagent fluorescence by Varioskan™ Flash Multimode reader (Thermo Scientific™). Genotypes were determined by real-time polymerase chain reaction (PCR) conducted in QuantStudio™ 6 (Applied Biosystems by Life Technologies™) with Custom TaqMan® SNP Genotyping Assays for rs27924520 and rs1183910, and Assays-by-DesignSM for rs4420638 (Applied Biosystems by Life Technologies™). For these analyses a high-throughput dried-down DNA method was used. Herein, 2.5 µL Master Mix (2X, TaqMan Genotyping Master Mix, Applied Biosystems by Life Technologies™) and 0.125 µL of a specific assay (TaqMan Genotyping 40X Assay, Applied Biosystems by Life Technologies™) and 2.375 µL Milli-Q (H₂O) per sample were added. The real-time PCR procedure included three stages: pre-read fluorescence measurement (30 seconds) at 60.0°C, 40 two-step cycles: DNA denaturation at 95.0°C (15 seconds) and amplification of SNP sequence of interest at 60.0°C (60 seconds) and post-read fluorescence measurement (30 seconds) at 60.0°C. Allelic discrimination was determined by the post-read stage fluorescence intensity using QuantStudio™ 6 genotyping software.

Statistical analyses

Descriptive statistics were generated using Statistical Package for Social Sciences (SPSS Inc., version 20.0. IBM corp. Chicago, IL, USA), while genetic analyses were performed using PLINK v1.07 (Purcell *et al*, 2007) and R (www.r-project.org). Missing values at baseline and psychopathology outcome variables were imputed using multiple imputation in SPSS. Ten imputed datasets were created based on independent and dependent variables. Analyses were conducted in each dataset and results were pooled according to Rubin's rule (Rubin, 1987). The Hardy-Weinberg equilibrium (HWE) threshold was set at $p > 0.05$. To comprehensively examine both single-SNP and cumulative effects of all three SNPs on psychopathology following ICU stay, the following analyses were carried out subsequently.

First, per-SNP linear regression models with SRIP and BDI-II scores as outcome variables were performed with the following covariates: sex, age, duration of ICU admission, treatment (dexamethasone vs. placebo administration) and genotype-treatment interaction. Treatment was included because of the potent anti-inflammatory properties of dexamethasone. The significance threshold was Bonferroni corrected ($\alpha = 0.05/3$; $\alpha = 0.017$) to account for the three SNPs tested.

Second, to model the cumulative effect of the three SNPs on PTSD and depression, we used genetic risk score (GRS) profiling (Purcell *et al*, 2009). Effect alleles were presented as “coded alleles”; effect sizes were presented as beta-values and obtained from the CRP GWAS (N=80,000 individuals; Dehghan *et al*, 2011) to calculate GRS in PLINK. GRS was regressed against log transformed SRIP and BDI-II scores to calculate the proportion of explained variance in psychopathology outcome. Two models were applied: the first model only included sex and age as covariates, while the second model included all eight variables mentioned before as covariates.

Third, to corroborate the results of our GRS model, we performed a fixed-effect (inverse variance weighted, IVW) meta-analysis in line with a recent MR study (Vaucher *et*

al, 2017) using the Mendelian Randomization package in R (Yavorska & Burgess, 2017). The two-sample MR IVW method reports estimates of causality between exposures and outcomes. All effect sizes were in standard deviation units for continuous traits and log odds ratios for disease and binary traits. The standard error (SE) was estimated using the delta method (Bautista *et al*, 2007; Thomas *et al*, 2007). Multiple sensitivity analyses validated the three MR assumptions (i.e., [1] the genetic marker is robustly associated with exposure, [2] the genetic marker is conditionally independent of outcome [pleiotropy], and [3] the genetic marker is conditionally independent of measured/unmeasured confounders), as well as the NO Measurement Error (NOME) assumption (Bowden *et al*, 2016). Moreover, the more robust MR-Egger method (Spring *et al*, 1989) was applied to investigate potential directional horizontal pleiotropy. The high I^2 statistic (>90% in our study) supports the MR assumption of NOME. In addition, leave-one-out analysis was performed (Stone, 1974). In line with the abovementioned quantitative traits studies, per-SNP logistic regression to assess single-SNP effects was performed first, followed by logistic regression on GRS calculated from the three SNPs, and concluded with fixed-effects meta-analysis.

Finally, to assess whether effects of CRP-associated SNPs are specific to post-ICU admission psychopathology or also generalizable to 14 other psychiatric disorders, we used the MR-base package (Hemani *et al*, 2016), aiming to investigate any causal relationships between CRP and such phenotypes, based on the abovementioned three leading CRP-associated SNPs. If these candidate SNPs could not be extracted from the statistical data summary, we extracted a proxy SNP instead (the most informative SNP having highest LD r^2 - value). The significance threshold was again Bonferroni corrected ($\alpha=0.05/14=0.0036$).

Results

Demographics and clinical characteristics

The study population consisted of 1093 subjects for whom signed informed consent, returned completed questionnaires and sufficient DNA were available (Figure S1). The median age of the participants was 69 years (interquartile range (IQR): 63-76) and ranged between 26 and 91 years. The majority of patients were male (78%). Dexamethasone was administered to 49.8 percent of the participants while 50.2 percent received placebo. Patients were admitted to the ICU for 5 to 1800 hours with a median duration of stay of 21 hours (IQR: 18.5-23.5). Demographic and clinical characteristics are displayed in Table 1.

Genotyping success rates and Hardy-Weinberg equilibrium

The genotyping success rates for rs2794520, rs4420638 and rs1183910, were 97.7, 96.5, and 97.5 percent, respectively. All three SNPs were in Hardy-Weinberg equilibrium (HWE; $p=1.0$; $p=0.076$, and $p=1.0$, respectively) and the minor allele frequencies (MAFs) were 0.3455, 0.1909 and 0.2935, which is in agreement with the 1000 Genomes project (<http://www.1000genomes.org>). Genotype distributions are presented in Table S1.

Mendelian randomization analyses

None of the three SNPs was individually associated with PTSD or depressive symptoms at the Bonferroni-corrected significance threshold ($\alpha=0.017$; Table 2a and 2b). rs2794520 showed nominal evidence of association with quantitative PTSD symptoms (β : 0.2142, $p=0.0325$) and with quantitative depression symptoms (β : 0.2203, $p=0.0273$): the CRP-decreasing T-allele (which is also the minor allele) was associated with increased risk of psychopathology following ICU stay (Figure 1a and 1b). Logistic regression showed no significant results for

the binary traits either: presence of the T-allele of rs2794520 tended to increase the risk of depression (OR=1.811, $p=0.051$) and PTSD (OR=1.409, $p=0.316$) non-significantly.

When applying GRS, the proportions of variances of quantitative and binary PTSD and depressive symptoms explained by the CRP loci were non-significant ($p>0.05$) and below 0.0035 in both models (Figure S2).

Meta-analysis of the effects of the three CRP SNPs on PTSD and depressive symptoms was similarly negative (Figure S3, Figure S4, and Table S2a). There was no evidence of heterogeneity ($p=0.02$). MR-Egger regression (Table S2b) consistently showed no causal effects: the I^2 statistic (indicating the level of instrument bias in the context of MR-Egger) was high ($>90\%$). Therefore, the expected relative dilution did not affect the standard MR-Egger analyses for our data. Directional horizontal pleiotropy of CRP and psychopathological outcomes was absent (p -pleiotropy >0.05). Leave-one-out sensitivity analyses (Figure S5) showed none of the SNPs altering pooled effect sizes, indicating reliable and stable meta-analytic results. In line with this, parallel binary trait analysis showed no association between either individual SNPs or GRS on the one hand and psychopathology outcomes on the other, pleading against a causal relation between CRP-levels and psychopathology.

Finally, estimation of causality between the three CRP SNPs and 14 other psychiatric disorders by MR-base showed that level of CRP does not significantly affect the occurrence of other neuropsychiatric diseases (Table 3). No directional horizontal pleiotropy effects were detected among CRP and these neuropsychiatric traits.

Discussion

The present study was designed to examine the potential effect of trait CRP on PTSD and depressive symptoms in a large cohort of ICU survivors (N=1093). Overall, no evidence for a causal relationship between trait CRP and psychopathology after ICU-stay was found. In addition, we demonstrated that these traits are unlikely to share non-polygenic genetic overlap. Finally, we showed that the absence of causal effects of plasma CRP also applies to other neuropsychiatric traits. Since these disorders share many risk factors, which further pleads against a role of CRP in the development of psychopathology. Considering the many MR assumptions, negative MR findings are particularly valuable (van der Weele *et al*, 2014). Provided the genetic variants are strongly associated with the exposure – which is the case in this study – negative MR findings more strongly advance insights into relationships between exposures and traits than positive MR findings (van der Weele *et al*, 2014). Moreover, a null association (with a narrow confidence interval) between a strong instrument and an outcome provides more robust evidence of no or a very small causal effect.

Several factors may explain these findings. First, being admitted to an ICU is commonly perceived as stressful and this may trigger the development of PTSD and depressive symptoms (Schelling *et al*, 2003; Davydow *et al*, 2008). Thus, environmental factors (e.g. illness severity and duration of stay) may be stronger determinants of psychiatric outcomes following ICU stay than genetic underpinnings. Elevated levels of CRP in the context of psychopathology as detected in previous studies (Danner *et al*, 2003; Eraly *et al*, 2014; Wium-Andersen *et al*, 2014) may also occur due to other mechanisms, such as reversed causation, where PTSD and/or depressive symptoms cause elevated CRP levels rather than vice versa. Upregulation of inflammatory markers – e.g. state CRP – could therefore still be part of the pathophysiological pathway involved with the development of stress-related psychopathology (Duivis *et al*, 2013; von Känel *et al*, 2007). Future studies combining

plasma CRP levels with MR could provide a more-refined understanding of the relationship between CRP levels and psychopathology (Almeida *et al*, 2009; Wium-Andersen *et al*, 2014). Furthermore, CRP-related genetic mechanisms other than single-locus effects – e.g., epistasis (for which this study was underpowered) and epigenetics – may influence the relationship between CRP and psychopathology. Finally, our power analysis indicates that our model had 80% power to detect an effect size of 0.007. This indicates that our study was adequately powered to detect medium to large effects, but underpowered to pick up very small effects (Freeman *et al*, 2013).

Although a positive association between CRP and psychopathology has been observed (Wium-Andersen *et al*, 2014; Ma *et al*, 2010), causal effects of CRP-associated loci on neuropsychiatric diseases had remained debatable. A recent MR study of CRP with multiple complex traits in a European study population, in which two CRP genetic risk scores as instrumental variables were used, showed no causality between CRP and autism, bipolar disorder, Parkinson's disease, major depressive disorder, and a negative effect on schizophrenia (i.e., elevated levels of CRP are not predisposing but in fact protective) (Prins *et al*, 2016). Similarly, in our MR-based study, a suggestive but nevertheless consistently negative effect on schizophrenia was detected ($p=0.014$, which was the lowest p -value among 14 psychiatric traits) (Dehghan *et al*, 2011; Ripke *et al*, 2014). Although the negative effect on schizophrenia was not significant after correction for multiple testing, the validation of this result requires further investigation of more CRP-associated SNPs. No significant directional horizontal pleiotropy for the three CRP-associated SNPs was detected in a broad selection of psychiatric disorders (p -pleiotropy >0.05), implying these psychiatric disorders and state CRP levels are not associated with the CRP genetic variants via separate pathways.

Since other studies implicate different CRP polymorphisms from the ones we investigated, comparison of our results with previous findings is challenging. For example,

rs1130864 (4kb away from rs2794520, $r^2=0.198$) was found to be associated with more PTSD symptoms in African American population. With regard to depressive symptoms, a limited number of studies have been conducted, showing ambiguous results. Three studies found no association between these genetic variants on CRP genes and depression (Halder *et al*, 2010; Luciano *et al*, 2010; Wium-Andersen *et al*, 2014), while one found CRP polymorphisms rs1800947 and rs3093059 to be associated with depression irrespective of plasma CRP levels (Ancelin *et al*, 2015).

It is important to bear in mind that this study addressed a cardiac surgery cohort. In general, these are relatively healthy patients who are only admitted to the ICU overnight. Nevertheless, cardiovascular disease has been associated with inflammatory dysregulation in general (Bot & Kuiper, 2017). Differentiation between the effect of ICU treatment and genetic predisposition for the development of PTSD and depression is therefore challenging in our study population. Targeting phenotypically more diverse cohorts of critically ill patients may result in a more fine-grained understanding of the relationship between trait CRP and psychopathology. On the other hand, strengths of our study comprise the investigation of the most strongly associated CRP genetic loci, the high genotyping success rates and the stringent and comprehensive statistical analyses including several sensitivity analyses, while correcting for multiple testing and relevant covariates.

In conclusion, based on our MR method it is unlikely that trait CRP and psychopathology following ICU stay are causally related or demonstrate high degrees of genetic overlap. Identification and investigation of novel CRP loci and inflammatory signalling pathways may result in a better understanding of biological mechanisms involved in the relationship between inflammation and psychopathology following ICU stay. Furthermore, a deeper understanding of the relationship between state and trait inflammatory processes on the one hand, and psychopathology on the other, may in the long run spur

identification of ICU patients at risk. Such knowledge in turn may open avenues for targeted preventative measures and treatments in these individuals at risk of developing psychopathology.

Funding and Disclosure

The authors declare no conflict of interest.

Acknowledgements

The authors gratefully acknowledge the time and effort of the centers that participated in this study. We thank Diederik van Dijk and Marian Joëls for giving us the time and opportunity to perform this study.

References

Almeida OP, Norman PE, Allcock R, van Bockxmeer F, Hankey GJ, Jamrozik K., *et al* (2009). Polymorphisms of the CRP gene inhibit inflammatory response and increase susceptibility to depression: the Health in Men Study. *International Journal of Epidemiology* 38: 1049-59.

Ancelin ML, Farré A, Carrière I, Ritchie K, Chaudieu I, Ryan J (2015). C-reactive protein gene variants: independent association with late-life depression and circulating protein levels. *Translational Psychiatry* 5(e499): 1-8.

Asimakopoulou E, Madianos M (2014). The prevalence of major depression-PTSD comorbidity among ICU survivors in five general hospitals of Athens: a cross-sectional study. *Issues in Mental Health Nursing* 35: 954-963.

Bautista LE, Smeeth L, Hingorani AD, Casas JP (2006). Estimation of bias in nongenetic observational studies using "mendelian triangulation". *Annals of Epidemiology* 16: 675-80.

Beck AT, Steer RA, Ball R, Ranieri W (1998). Comparison of Beck Depression Inventories - IA and -II in psychiatric outpatients. *Journal of Personality Assessment* 67: 588-597.

Bot I, Kuiper J (2017). Stressed brain, stressed heart? *The Lancet* 389: 770-771.

Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR (2016). Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I^2 statistic. *International Journal of Epidemiology*

45: 1961-1974.

Danner M, Kasl SV, Abramson JL, Vaccarino V (2003). Association Between Depression and Elevated C-Reactive Protein. *Psychosomatic Medicine* 65: 347-356.

Davydow DS, Gifford JM, Desai SV, Needham DM, Bienvenu OJ (2008). Posttraumatic stress disorder in general intensive care unit survivors: a systematic review. *General Hospital Psychiatry* 30: 421-434.

Davydow DS, Gifford JM, Desai SV, Bienvenu OJ, Needham DM (2009). Depression in general intensive care unit survivors: a systematic review. *Intensive Care Medicine* 35: 796-809.

Davydow DS, Zatzick D, Hough CL, Katon WJ (2013). A longitudinal investigation of posttraumatic stress and depressive symptoms over the course of the year following medical-surgical intensive care unit admission. *General Hospital Psychiatry* 35: 226-232.

de Haan HG, Siegerink B, van Hylckama Vlieg A (2014). Mendelian Randomization. *Nederlands Tijdschrift voor Geneeskunde*, 158: 1-6.

Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, *et al* (2011). Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. *Circulation* 123: 731-738.

Dieleman JM, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, *et al*

(2012). Intraoperative High-Dose Dexamethasone for Cardiac Surgery. A Randomized Controlled Trial. *Journal of the American Medical Association* 308: 1761-1767.

Duivis HE, Vogelzangs N, Kupper N, de Jonge P, Penninx BWJH (2013). Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: Findings from the Netherlands Study of Depression and Anxiety (NESDA). *Psychoneuroendocrinology* 38: 1573-1585.

Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, *et al* (2009). Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. *Journal of the American Medical Association* 302: 37-48.

Eraly SA, Nievergelt CM, Maihofer AX, Barkauskas DA, Biswas N, Agorastos A, *et al* (2014). Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. *Journal of the American Medical Association Psychiatry* 71: 423-431.

Freeman G, Cowling BJ, Schooling CM (2013). Power and sample size calculations for Mendelian randomization studies using one genetic instrument. *Int J Epidemiology* 42: 1157-1163.

Halder I, Marsland AL, Cheong J, Muldoon MF, Ferrell RE, Manuck SB (2010). Polymorphisms in the CRP gene moderate an association between depressive symptoms and circulating levels of C-reactive protein. *Brain Behaviour and Immunity* 24: 160-167.

Hemani G, Zheng J, Wade KH, Laurin C, Elsworth B, Burgess S, *et al.* (2016). MR-base: a

platform for systemic causal inference across the phenome using billions of genetic associations. Preprint. doi: 10.1101/078972

Hovens JE, Bramsen I, van der Ploeg HM (2002). Self-rating inventory for posttraumatic stress disorder: review of the psychometric properties of a new brief Dutch screening instrument. *Perceptual and Motor Skills* 94: 996-1008.

Iwashyna TJ (2010). Survivorship Will Be the Defining Challenge of Critical Care in the 21st Century. *Annals of Internal Medicine* 153: 204-205.

von Känel R, Hepp U, Kraemer B, Traber R, Keel M, Mica L, Schnyder U (2007). Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. *Journal of Psychiatric research* 41: 744-752.

Kasapis C, Thompson PD (2004). The Effects of Physical Activity on Serum C-Reactive Protein and Inflammatory Markers: A Systematic Review. *Journal of the American College of Cardiology* 45: 1563-1569.

King DE, Egan BM, Geesey ME (2003). Relation of Dietary Fat and Fiber to Elevation of C-Reactive Protein. *The American Journal of Cardiology* 92: 1335-1339.

van Kippersluis H, Rietveld CA (2017). Pleiotropy-robust Mendelian randomization. *International Journal of Epidemiology*. doi: 10.1093/ije/dyx002. [Epub ahead of print]

Kok L, Hillegers MH, Veldhuijzen DS, Cornelisse S, Nierich AP, van der Maaten JM, *et al*

(2016). The effect of dexamethasone on symptoms of posttraumatic stress disorder and depression after cardiac surgery and intensive care admission: longitudinal follow-up of a randomized controlled trial. *Critical Care Medicine* 44: 512-520.

Luciano M, Houlihan LM, Harris SE, Gow AJ, Hayward C, Starr JM, *et al* (2010). Association of existing and new candidate genes for anxiety, depression and personality traits in older people. *Behaviour and Genetics* 40: 518-532.

Ma Y, Chiriboga DE, Pagoto SL, Rosal MC, Li W, Merriam PA, *et al* (2010). Association between Depression and C-Reactive Protein. *Cardiology Research and Practise* 2011: 1-8.

Michopoulos V, Rothbaum AO, Jovanovic T, Almlil LM, Bradley B, Rothbaum BO, *et al* (2015). Association of CRP Genetic Variation and CRP Level With Elevated PTSD Symptoms and Physiological Responses in a Civilian Population With High Levels of Trauma. *American Journal of Psychiatry* 172: 353-362.

Miller AH, Maletic V, Raison CL (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. *Biological Psychiatry* 65: 732-741.

Oeyen SG, Vandijck DM, Benoit DD, Annemans L, Decruyenaere JM (2010). Quality of life after intensive care: A systematic review of the literature. *Critical Care Medicine* 38: 2386-2400.

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, *et al* (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. *American*

Journal of Human Genetics 81: 559-575.

Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, *et al* (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 460: 748-52.

Prins BP, Abbasi A, Wong A, Vaez A, Nolte I, Franceschini N, *et al* (2016) Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study. *PLoS Medicine* 13: e1001976.

Raison CL, Miller AH (2011). Is depression an inflammatory disorder? *Current Psychiatry Reports* 13: 467-475.

Ripke S, Neale BM, Corvin A, Walters JT, Farh KH, Holmans PA, *et al* (2014). Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511: 421-427.

Rubin DB (1987): Multiple Imputation for Nonresponse in Surveys. New York, Wiley & Sons.

Schelling G, Richter M, Roozendaal B, Rothenhäusler H-B, Krauseneck T, Stoll C, *et al* (2003). Exposure to high stress in the intensive care unit may have negative effects on health-related quality-of-life outcomes after cardiac surgery. *Critical Care Medicine* 31: 1971-1980.

Spring B, Lemon M, Weinstein L, Haskell A (1989). Distractibility in schizophrenia: state and

trait aspects. *The British Journal of Psychiatry Supplement* 5: 63-8.

Stone M (1974). Cross-validatory choice and assessment of statistical predictions. *Journal of the royal statistical society. Series B (Methodological)*: 111-147.

Thomas DC, Lawlor DA, Thompson JR (2007). Re: Estimation of bias in nongenetic observational studies using "Mendelian triangulation" by Bautista et al. *Annals of Epidemiology* 17: 511-3.

Vaucher J, Keating BJ, Lasserre AM, Gan W, Lyall DM, Ward J, *et al* (2017). Cannabis use and risk of schizophrenia: a Mendelian randomization study. *Molecular Psychiatry*. doi: 10.1038/mp.2016.252. [Epub ahead of print]

van der Weele TJ, Tchetgen EJT, Cornelis M, Kraft P (2014). Methodological Challenges in Mendelian Randomization. *Epidemiology* 25: 427-435.

Wium-Andersen MK, Ørsted DD, Nielsen SF, Nordestgaard BG (2013). Elevated C-Reactive Protein Levels, Psychological Distress, and Depression in 73131 Individuals. *Journal of the American Medical Association Psychiatry* 70: 176-184.

Wium-Andersen MK, Ørsted DD, Nordestgaard BG (2014). Elevated C-reactive protein, depression, somatic diseases, and all-cause mortality: a mendelian randomization study. *Biological Psychiatry* 76: 249-257.

Yavorska OO, Burgess S (2017). MendelianRandomization: an R package for performing

Mendelian randomization analyses using summarized data. International Journal of Epidemiology. doi: 10.1093/ije/dyx034. [Epub ahead of print]

Figure Legends

Figure 1a. This graph depicts how subjects homozygous for the minor T-allele of rs2794520 seem vulnerable to develop PTSD symptoms and to promote the development of depressive symptoms after ICU stay. The y-axis represents mean total score of the SRIP questionnaire and thus severity of PTSD symptoms, whereas genotypes of rs2794520 are shown on the x-axis.

Figure 1b: This graph depicts how subjects homozygous for the minor T-allele of rs2794520 seem vulnerable to develop depressive symptoms and to promote the development of depression symptoms after ICU stay. The y-axis represents mean total score of the BDI-II questionnaire and thus severity of depressive symptoms, whereas genotypes of rs2794520 are shown on the x-axis.

Figure S1. ‘n’ represents numbers of patients included or excluded. Arrows display included patients, while lines present excluded patients.

Figure S2. R^2 : multiple R^2 in linear regression, Nagelkerke’s pseudo R^2 in logistical regression. Dichotomous trait for PTSD and depression using validated cut-off scores. Model 1 contains GRS, age, and sex as covariates. Model 2 contains GRS, age, sex, length of ICU stay, dexamethasone vs. placebo treatment and genotype-treatment interaction as covariates.

Figure S3. Forest plots of meta-analysis (fixed-effects, inverse variance) results for the three SNPs on PTSD and depressive symptoms after ICU stay.

Figure S4. snp1: rs4420638, snp2: rs2794520, snp3: rs1183910. SNP-exposure (associations with *CRP*) and SNP-outcome (associations with psychopathology outcomes) coefficients used in Mendelian Randomization analysis. Error bars (95% Confidence Interval) are reported for

each association. The blue lines represent fix-effect meta-analysis (inverse variance weighted; IVW) model estimations.

Figure S5. Forest plots of leave-one-out sensitivity analysis (fixed-effects, inverse variance) results for the three SNPs on PTSD and depressive symptoms after ICU stay.

Table Legends

Table 1: Values are presented as either ratios or medians with inter quartile ranges (IQR) and full ranges. BDI-II, Beck Depression Inventory II score; ICU, intensive care unit; SRIP, Self-Report Inventory for PTSD score.

Table 2a: Displayed are standardized beta-coefficients (β), standard error (SE) and p-values (p). The suggestively significant finding is in italics.

Table 2b: Displayed are standardized odds ratio (OR), standard error (SE) and p-values (p). The suggestively significant finding is in italics.

Table 3. Displayed are PubMed ID (PMID), sample size, test statistics used as instruments from GWAS studies for psychosocial disorders; odd ratio (OR), 95% confidence interval (95%CI), nominal p-values (p-value) from MR-base analyses with IVW models, and p-values for pleiotropy (p-pleiotropy) test from MR-base analyses with Egger model.

Table S1. Observed minor allele frequencies (MAFs) based on our study population. Expected MAFs are according to the 1000 Genomes project.

Table S2a: shown are the results for the meta-analysis (fixed-effects, inverse variance) for the three SNPs on PTSD and depressive symptoms after ICU stay.

Table S2b: shown are the results for the meta-analysis (MR-Egger regression) for the three SNPs on PTSD and depressive symptoms after ICU stay.

Figure 1a. Means plot of PTSD symptoms per genotype.

Figure 1b. Means plot of depressive symptoms per genotype.

Table 1. Demographic and clinical characteristics of the study population (N=1093).

Characteristic	N (%)	Median (IQR)	Range
Demographics			
Age (years)	-	69.6 (63.1-76.1)	26-91
Sex – Male	854 (78.1)	-	-
ICU			
Dexamethasone treatment	544 (49.8)	-	-
Duration of ICU stay (hours)	-	21.0 (18.5-23.5)	5-1800
Self-reported psychiatric history			
Depression	22 (2.0)	-	-
Bipolar Disorder	6 (0.5)	-	-
Anxiety Disorder	17 (1.6)	-	-
Other Psychiatric Disorders	13 (1.2)	-	-
Outcome measures (total scores)			
SRIP		26.0 (21.5-30.5)	22-78
BDI-II		5.0 (1.5-8.5)	0-51

**Table 2a. Association between CRP-associated SNPs and psychopathology symptoms:
linear regression.**

PTSD				Depression symptoms		
SNP	β	SE	<i>p</i>	β	SE	<i>p</i>
rs2794520	<i>0.2142</i>	<i>0.1001</i>	<i>0.0325</i>	<i>0.2203</i>	<i>0.0997</i>	<i>0.0273</i>
rs4420638	0.0429	0.1238	0.7291	-0.2168	0.1265	0.8640
rs1183910	-0.006	0.1186	0.9570	0.0154	0.1151	0.8933

**Table 2b: Association between CRP-associated SNPs and psychopathology symptoms:
logistic regression.**

PTSD				Depression symptoms		
SNP	OR	SE	<i>p</i>	OR	SE	<i>p</i>
rs2794520	<i>1.4090</i>	<i>0.3418</i>	<i>0.3161</i>	<i>1.8110</i>	<i>0.3047</i>	<i>0.0512</i>
rs4420638	1.127	0.3821	0.5330	1.2890	0.3716	0.4946
rs1183910	1.187	0.4069	0.6741	1.3152	0.3307	0.4080

Table 3. Two sample MR results from MR-base for CRP and various other neuropsychiatric disorders.

Phenotypes	PMID	sample size	test statistics	OR	95%CI	p-value	p-pleiotropy
Schizophrenia	25056061	82,315	log odds	0.896	0.820-0.978	0.014	0.356
Anorexia nervosa	24514567	17,767	log odds	0.958	0.594-1.543	0.858	0.965
Bulimia nervosa	23568457	2,442	log odds	0.983	0.923-1.047	0.603	0.591
Neuroticism	25993607	160,958	arbitrary score	0.983	0.907-1.066	0.685	0.761
Alzheimer's disease	24162737	54,162	log odds	0.239	0.006-8.482	0.432	0.122
Bipolar disorder	21926972	16,731	log odds	1.209	0.929-1.576	0.158	0.621
Parkinson's disease	19915575	5,691	log odds	0.651	0.459-0.924	0.017	0.355
Autism	23453885	29,415	log odds	1.091	0.832-1.430	0.528	0.624
	PGC 2015	10,263	log odds	1.077	0.896-1.349	0.548	0.560
Major depressive disorder	22472876	18,759	log odds	1.080	0.914-1.276	0.366	0.758
Depressive symptoms	27089181	161,460	SD	1.002	0.971-1.033	0.910	0.782
Subjective well being	27089181	298,420	SD	1.019	0.997-1.042	0.093	0.994
Internalizing problems	24839885	4,569	NA	0.973	0.814-1.162	0.759	0.563

Amyotrophic lateral sclerosis	27455348	36,052	log odds	1.014	0.986-1.043	0.339	0.373
PTSD (European population)	25904361	more than 5,000	log odds	1.078	0.811-1.432	0.607	0.373

Supplementary Material and Methods

Figure S1. Flow chart of recruitment of participants.

Figure S2. Proportion of variance in psychopathology explained by polygenic risk scores (GRS) obtained from the three CRP-associated SNPs using individual-level genetic data.

Figure S3. Meta-analysis forest plots (fixed-effects, inverse variance).

S3a. CRP with quantitative SRIP score.

S3b. CRP with binary PTSD outcome.

S3c. CRP with quantitative BDI-II score.

S3d. CRP with binary depression outcome.

Figure S4. Scatter plots of associations between three SNPs, CRP, and psychopathology.

S4a. Scatter plot for quantitative SRIP score.

S4b. Scatter plot for binary PTSD outcome.

S4c. Scatter plot for quantitative BDI-II score.

S4d. Scatter plot for binary depression outcome.

Figure S5. Forest plots of leave-one-out analysis.

S5a. CRP with quantitative SRIP score.

S5b. CRP with binary PTSD outcome.

S5c. CRP with quantitative BDI-II score.

S5d. CRP with binary depression outcome.

Table S1. Genotyping information.

SNP	Genotype	Distribution (N, frequency)	Minor Allele	Observed MAF	Expected MAF
rs2794520	TT/TC/CC	129(0.12) / 491(0.45) / 464(0.43)	T	0.3455	0.3421
rs4420638	GG/GA/AA	48(0.05) / 313(0.29) / 710(0.66)	G	0.1909	0.1510
rs1183910	AA/AG/GG	94(0.09) / 451(0.41) / 537(0.50)	A	0.2935	0.2955

Table S2a. Meta-analysis summary statistics.

Phenotype	Effect size	SE	CI (95%)	<i>p</i>	<i>p-het</i>
Quantitative SRIP score	-0.517	0.359	-1.221-0.187	0.150	0.271
Binary PTSD outcome	-1.110	1.167	-3.397-1.178	0.158	0.831
Quantitative BDI-II score	-0.021	0.360	-0.728-0.685	0.979	0.020
Binary depression outcome	-0.2074	1.064	-4.162-0.017	0.124	0.563

Table S2b. Meta-analysis summary statistics.

Phenotype	Effect size	SE	CI (95%)	p-effect	p-pleiotropy	I ²	p-het
Quantitative SRIP score	0.650	2.646	-4.535-5.836	0.806	0.652	96.5%	0.139
Binary PTSD outcome	1.642	5.709	-9.548-12.832	0.774	0.168	97.6%	0.721
Quantitative BDI-II score	3.727	3.315	-2.770-10.224	0.261	0.248	95.5%	0.067
Binary depression outcome	1.852	5.309	-8.553-12.256	0.727	0.323	94.6%	0.445